IQVIA Institute for Human Data Science

📢 Now live: Pathway to Success in Cancer Treatment, Achieving Radioligand Capacity and Readiness. This paper is a summary of highlights from a multi-stakeholder public working session held at The European Parliament On April 11, 2024, and subsequent discussions on IQVIA Institute’s published report, The State of Radioligand Therapy Readiness in Europe. Read what the experts had to say about necessary actions as innovative therapies continue to enter the cancer care paradigm: https://bit.ly/3B0W2SO. #CancerResearch

What are the pros and cons of reprioritizing and increasing the clinical trial country footprint? Find out at IQVIA Institute’s multi-stakeholder webinar. Panelists will discuss global clinical trial diversification, enrollment trends, and country readiness. 📅 September 9, 2024 ⌚ 10:00 a.m. – 11:30 a.m. EDT 📌 Virtual Confirmed speakers:. 🎙️Clémentine Body 🎙️ Luis Augusto Russo 🎙️ Vasee Moorthy, Ph.D 🎙️ Ashley H Williams 🎙️ Alison Liddy (Ph.D), https://bit.ly/3yW0Ubv #ClinicalTrials

🌍 Join the IQVIA Institute for a multi-stakeholder panel discussion on Hematologic Cancer Opportunities for Patient Equality (HOPE): Achieving equitable and timely access to hematological cancer therapies. This critical discussion will focus on actions and policies that are needed to overcome the key barriers that limit hematological cancer therapy access. 📅 17 September 2024 ⌚10:30 a.m. – 12:00 p.m. CET (Geneva) Confirmed speakers: 🎙️ Antonella Cardone 🎙️ Kathleen Gesy 🎙️ Richard Price 🎙️ Maciej Miłkowski Moderator: Murray Aitken Register here: https://bit.ly/3Z7Tz36.

🔍 Join the IQVIA Institute for a multi-stakeholder webinar, which follows the recent release of Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Panelists will discuss key challenges, patient access, and what's next for the sector. 📅 September 5, 2024 ⌚ 10:00 AM - 11:30 AM EST Confirmed speakers: 🎙️ Maria Santaella, Ph.D. 🎙️ Mark Trusheim, MS 🎙️ Joshi Venugopal, Ph.D. 🎙️ Monica Veldman 🎙️ Amritha Jaishankar, Ph.D. Moderated by: Murray Aitken Register here: https://bit.ly/3AHDneI.

How can we strengthen Europe’s position as a global leader in oncology trials? The IQVIA Institute's Pre-ESMO Symposium will tackle this crucial conversation—open to the public at no cost. Register here: https://bit.ly/477s0J8. #ESMO2024 #oncology #globalhealth

🩸 Why is robust clinical trial evidence crucial for appropriate payer/Health Technology Assessment (HTA) assessments in hematologic cancer? IQVIA Institute’s Hematologic Cancer Opportunities for Patient Equality (HOPE) report highlights why clinical trial methodology and efficacy outcomes are key factors impacting access and reimbursement for hematology drugs in markets like France and Spain. Read the report here: https://bit.ly/474o6ka. #GlobalHealth #Oncology #PatientEquity

📊 When designing long-term follow-up studies for cell and gene therapies, therapy characteristics, disease factors, and the operating environment play a crucial role. This exhibit from the Strengthening Pathways for Cell and Gene Therapies report shows the elements to consider. Download the report here: https://bit.ly/3X2Ojv1.

📢 Join IQVIA Institute for a multi-stakeholder webinar to discuss our new report, Rethinking Clinical Trial Country Prioritization. Panelists will discuss global clinical trial diversification, enrollment trends, and country readiness. 📅 September 9, 2024 ⌚ 10:00 a.m. – 11:30 a.m. EDT 📌 Virtual Confirmed speakers:. 🎙️ Adam Chasse, MHA 🎙️ Luis Augusto Russo, MD 🎙️ Vasee Moorthy, Ph.D 🎙️ Ashley Williams 🎙️ Alison Liddy, H.Dip https://bit.ly/3XjzPYV #ClinicalTrials

Achieving health equity is an important priority for the healthcare ecosystem, especially the life sciences industry; however, it’s complex and challenging, and there is uncertainty about how to measure and deliver sustained progress in a rapidly evolving field. To address the challenges and opportunities around health equity, the IQVIA Institute convened a life sciences industry roundtable on April 18, 2024, to discuss three important questions: • Where have we been able to achieve success toward health equity, and why? • How do we measure the impact and ROI of health equity investments? • What are the greatest challenges, either internal or external, to advancing health equity initiatives and to addressing these challenges? To learn what stakeholder had to say download the report here: https://bit.ly/4799U9S

Europe has lost significant share of the global oncology industry-sponsored interventional trial activity over the past five years, primarily to the U.S., China, and Australia. Find out what initiatives are currently underway across Europe to improve its involvement in oncology trials at IQVIA Institute's Pre-ESMO 2024 Symposium. 📅 Date: September 13, 2024 🕛 9:00 - 11:30 a.m. CEST 📍 Location: Hotel Barceló Sants, Barcelona, Spain and Virtual  Speakers confirmed to date: 🎙️ Bettina Ryll, Ph.D 🎙️ Josep Tabernero, MD, Ph.D. 🎙️ José Luis García, MD, Ph.D. 🎙️ Elizabeth Theogaraj, Ph.D. 🎙️ Moderator: Murray Aitken, Executive Director, IQVIA Institute for Human Data Science This event is open to the public at no cost.  Register here: https://bit.ly/4dVXqEI.